Hanmi Pharm signs modified agreement of long-acting antidiabetic with Sanofi

Published: 2017-01-02 11:39:15

Updated: 2017-01-02 11:39:15

Hanmi Pharm(CEO Kwan-Soon Lee) announced on the 29^th that it signed a partial modification of the license agreement made on November 2015 for ‘Quantum Project,’ a long-acting antidiabetic portfolio, with Sanofi.

According to the modified agreement, development milestones for one of the 3 drug candidates, a new GLP-1 antidiabetic ‘efpeglenatide,’ will be reduced and Hanmi will pay for a part of...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.